Press

PharmaTher Provides Research and Development Update and Milestones for 2021

Jun 11 • 6 min read

Quick Take: PharmaTher has announced an update on the research and development of its psychedelics product. PharmaTher Holdings Ltd. (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to provide an update on the research and development initiatives of its psychedelic product programs and upcoming milestones for 2021. “We are well-positioned, both financially and operationally,…

Red Light Holland Closes Acquisition of 80% of Happy Caps Mushroom Farm – Specializing in Grow-At-Home Mushroom Kits

Jun 11 • 4 min read

Quick Take: Red Light Holland has closed on a deal with Happy Caps Mushroom Farm. This deal will give Red Light Holland an 80% stake in Happy Caps. Red Light Holland Corp. (CSE: TRIP), an Ontario-based corporation engaged in the production, growth and sale of a premium brand of magic truffles to the legal, recreational…

Goodness Growth Holdings Subsidiary Resurgent Biosciences Announces Planned Expansion into Psychedelics Research and IP Development

Jun 9 • 2 min read

Quick Take: Goodness Growth Holdings has announced that their subsidiary Resurgent Biosciences plans to expand its intellectual property development and clinical research efforts into psychedelic medicine. Goodness Growth Holdings, Inc. (CSE: GDNS), a physician-led, science-focused cannabis company and IP incubator, today announced that its subsidiary, Resurgent Biosciences (“Resurgent”), plans to expand its intellectual property development…

American Journal of Psychiatry Publishes International Ketamine and Esketamine Treatment Guidance Led by Braxia Scientific CEO Dr. Roger Mcintyre

Jun 9 • 3 min read

Quick Take: The American Journal of Psychiatry has published international ketamine and esketamine treatment guidelines. These guidelines were developed and led by Braxia’s CEO Dr. Roger McIntyre, M.D. along with other medical experts across the world. Braxia Scientific Corp. (CSE: BRAX), a medical research company with clinics providing novel ketamine treatments for persons with depression…

MindMed Announces Chief Executive Officer Transition

Jun 9 • 5 min read

Quick Take: MindMed CEO and co-founder J.R. Rahn is stepping down as chief executive officer. Chief development officer Robert Barrow will assume the position of CEO with immediate effect. Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic inspired medicines, announces that J.R. Rahn, the Company’s co-founder…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441